A top podcast for healthcare leaders, with over one million downloads, Radio Advisory is your weekly download on how to untangle the industry's most pressing challenges to help leaders like you make the best business decisions for your organization. From unpacking major trends in care delivery—like site-of-care shifts and the rise of high-cost drugs—to demystifying stakeholder dynamics, to shining a spotlight on priorities that may get overlooked, we're here to help. Our hosts and seasoned r ...
…
continue reading
MP3•Episode home
Manage episode 486579932 series 2797294
Content provided by Informa TechTarget. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Informa TechTarget or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.
Featuring: Sara Heath, executive editor, Xtelligent Healthcare
Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare
In today’s episode, we’ll cover…
- The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions
- Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications
- Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections
and more!
References:
- Anticipating the healthcare reach of GLP-1 receptor agonists
- Are compounded GLP-1 drugs safe?
- FDA winds down GLP-1 compounding policies
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
To watch the video clips of our podcast, subscribe to our YouTube channel, @HealthcareStrategies.
122 episodes